In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 41 to 50 of 419

Sort by

Type: GuidanceRemove Type: Guidance filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]	Technology appraisal guidance	TBC
Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476]	Technology appraisal guidance	8 December 2027
Belzutifan with pembrolizumab for adjuvant treatment of clear cell renal cell carcinoma after nephrectomy [ID6645]	Technology appraisal guidance	TBC
Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481]	Technology appraisal guidance	13 January 2027
Benralizumab for previously treated severe nasal polyps [ID1659]	Technology appraisal guidance	TBC
Benralizumab to reduce exacerbations in moderate to very severe chronic obstructive pulmonary disease [ID1394]	Technology appraisal guidance	TBC
Bepirovirsen for treating chronic hepatitis B [ID6608]	Technology appraisal guidance	TBC
Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]	Technology appraisal guidance	15 July 2026
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen in people 5 to 17 years [ID6537]	Technology appraisal guidance	26 August 2026
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]	Technology appraisal guidance	20 February 2019

Results per page

10
25
50
All